TABLE I.
Demographic and Clinical Characteristics of the Sample
| Paroxetine |
Mirtazapine |
|||||||
|---|---|---|---|---|---|---|---|---|
| rs1360780 | CC (n = 57) | CT (n = 52) | TT (n = 13) | P-value | CC (n = 44) | CT (n = 69) | TT (n = 11) | P-value |
| Age (years, SD) | 73 (5.01) | 71 (5.21) | 74 (4.44) | 0.151 | 72 (5.98) | 72 (5.73) | 71 (4.21) | 0.734 |
| Gender (F/M) | 28/29 | 30/22 | 7/6 | 0.699 | 22/22 | 35/34 | 4/7 | 0.667 |
| Ethnicity (Caucasian/other) | 53/4 | 44/8 | 12/1 | 0.294 | 41/3 | 66/3 | 10/1 | 0.391 |
| Final daily dose (mg, SD) | 30.89 (9.56) | 28.80 (9.94) | 28.00 (9.56) | 0.419 | 32.2 (11.64) | 30.44 (11) | 31.74 (11.72) | 0.718 |
| Baseline HDRS-17 (SD) | 23.09 (3.71) | 21.92 (3.33) | 21.38 (3.5) | 0.118 | 21.84 (3.54) | 22.61 (3.56) | 21.73 (2.9) | 0.459 |
| Baseline HDRS-21 (SD) | 24.86 (4.63) | 23.35 (4.04) | 22.85 (3.76) | 0.114 | 23.32 (4.11) | 24.19 (4.25) | 23.00 (3.19) | 0.447 |
| Paroxetine |
Mirtazapine |
|||||||
|---|---|---|---|---|---|---|---|---|
| rs3800373 | AA (n = 58) | CA (n = 53) | CC (n = 11) | P-value | AA (n = 48) | CA (n = 65) | CC (n = 11) | P-value |
| Age (years, SD) | 72 (4.93) | 72 (5.41) | 74 (3.96) | 0.285 | 71.09 (4.18) | 72 (5.67) | 72 (6.06) | 0.855 |
| Gender (F/M) | 29/29 | 29/24 | 7/4 | 0.681 | 5/6 | 31/34 | 25/23 | 0.869 |
| Ethnicity (Caucasian/other) | 54/4 | 45/8 | 10/1 | 0.296 | 10/1 | 62/3 | 45/3 | 0.385 |
| Final daily dose (mg, SD) | 28.00 (7.82) | 28.80 (9.94) | 30.89 (9.56) | 0.419 | 31.74 (11.72) | 30.56 (11.13) | 31.88 (11.45) | 0.817 |
| Baseline HDRS-17 (SD) | 23.22 (3.73) | 21.66 (3.19) | 21.73 (2.90) | 0.049 | 21.55 (2.88) | 22.68 (3.52) | 21.85 (3.58) | 0.365 |
| Baseline HDRS-21 (SD) | 25.09 (4.77) | 22.96 (3.67) | 23.27 (3.90) | 0.029 | 22.82 (3.13) | 24.26 (4.18) | 23.33 (4.21) | 0.361 |